Robert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.
Robert DeBernardo, MD
Advertisement
Articles by Robert DeBernardo, MD
Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.
Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.
Advertisement
Latest Updated Articles
Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian CancerPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5